CHRDL2 antibody (AA 351-429) (Cy5.5)
Quick Overview for CHRDL2 antibody (AA 351-429) (Cy5.5) (ABIN750258)
Target
See all CHRDL2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 351-429
-
Cross-Reactivity
- Mouse, Rat
-
Predicted Reactivity
- Human,Cow,Sheep
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human CHRDL2
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- CHRDL2 (Chordin-Like 2 (CHRDL2))
-
Alternative Name
- CHRDL2
-
Background
-
Synonyms: BNF1, Breast tumor novel factor 1, CHL2, chordin like 2, Chordin like protein 2 precursor, Chordin related protein 2, CRDL2_HUMAN.
Background: CHRDL2 is a novel chordin like protein that can act as a BMP antagonist. Amember of the chordin family of proteins, it contains a signal peptide andthree CR (cysteine-rich repeat) domains. When expressed as a recombinantprotein it is secreted and binds to activin A, but not to BMP-2, -4, -6. Differential expression has been detected in developing chondrocytes, myoblasts, osteoblasts, and osteoarthritic joints. Complex alternative splicing of CHRDL2 potentially results in distinct isoforms that differ at their C termini, in the expression of signal peptide, and in the content of CR domains. CHRDL2 was originally characterized as a novel protein exclusively expressed in breast, lung, and colon tumors.
-
Gene ID
- 25884
Target
-